Catecholamines may undergo iron-promoted oxidation resulting in formation of reactive intermediates (aminochromes) capable of redox cycling and reactive oxygen species (ROS) formation. Both of them induce oxidative stress resulting in cellular damage and death. Iron chelation has been recently shown as a suitable tool of cardioprotection with considerable potential to protect cardiac cells against catecholamine-induced cardiotoxicity. However, prolonged exposure of cells to classical chelators may interfere with physiological iron homeostasis. Prochelators represent a more advanced approach to decrease oxidative injury by forming a chelating agent only under the disease-specific conditions associated with oxidative stress. Novel prochelator (lacking any iron chelating properties) BHAPI [(E)-Ń-(1-(2-((4-(4,4,5,5-tetramethyl-1,2,3-dioxoborolan-2-yl)benzyl)oxy)phenyl)ethylidene) isonicotinohydrazide] is converted by ROS to active chelator HAPI with strong iron binding capacity that efficiently inhibits iron-catalyzed hydroxyl radical generation. Our results confirmed redox activity of oxidation products of catecholamines isoprenaline and epinephrine, that were able to activate BHAPI to HAPI that chelates iron ions inside H9c2 cardiomyoblasts. Both HAPI and BHAPI were able to efficiently protect the cells against intracellular ROS formation, depletion of reduced glutathione and toxicity induced by catecholamines and their oxidation products. Hence, both HAPI and BHAPI have shown considerable potential to protect cardiac cells by both inhibition of deleterious catecholamine oxidation to reactive intermediates and prevention of ROS-mediated cardiotoxicity.

Charles University Prague Faculty of Pharmacy in Hradec Králové Heyrovského 1203 500 05 Hradec Králové Czechia

Duke University Department of Chemistry 124 Science Dr Durham NC 22708 USA

Zobrazit více v PubMed

Adamcova M, Simunek T, Kaiserova H, Popelova O, Sterba M, Potacova A, Vavrova J, Malakova J, Gersl V. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology. 2007;237:218–228. PubMed

Allen DR, Wallis GL, McCay PB. Catechol adrenergic agents enhance hydroxyl radical generation in xanthine oxidase systems containing ferritin: implications for ischemia/reperfusion. Arch Biochem Biophys. 1994;315:235–243. PubMed

Behonick GS, Novak MJ, Nealley EW, Baskin SI. Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes). J Appl Toxicol. 2001;21(Suppl 1):S15–22. PubMed

Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010;23:1105–1114. PubMed

Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med. 1992;13:391–405. PubMed

Bureš J, Jansová H, Stariat J, Filipský T, Mladěnka P, Šimůnek T, Kučera R, Klimeš J, Wang Q, Franz KJ, Kovaříková P. LC-UV/MS methods for the analysis of prochelator boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). J Pharm Biomed Anal. 2015;105:55–63. PubMed PMC

Buss JL, Hermes-Lima M, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv Exp Med Biol. 2002;509:205–229. PubMed

Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Eng J Med. 1984;311:819–823. PubMed

Costa VM, Carvalho F, Bastos ML, Carvalho RA, Carvalho M, Remiao F. Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr Med Chem. 2011;18:2272–2314. PubMed

Dhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fund Clin Pharmacol. 2010;24:539–546. PubMed

Galey JB. Recent advances in the design of iron chelators against oxidative damage. Mini Rev Med Chem. 2001;1:233–242. PubMed

Galey JB, Dumats J, Beck I, Fernandez B, Hocquaux M. N,N'-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an ‘oxidative stress activatable” iron chelator in vitro. Free Radic Res. 1995;22:67–86. PubMed

Ganong WF. Review of medical physiology. McGraw-Hill Medical; New York ; London: 2005.

Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195–3203. PubMed

Golabchi A, Sarrafzadegan N. Takotsubo cardiomyopathy or broken heart syndrome: A review article. J Res Med Sci. 2011;16:340–345. PubMed PMC

Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford University Press; Oxford ; New York: 2007.

Haskova P, Kovarikova P, Koubkova L, Vavrova A, Mackova E, Simunek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radic Biol Med. 2011;50:537–549. PubMed

Hatcher HC, Singh RN, Torti FM, Torti SV. Synthetic and natural iron chelators: therapeutic potential and clinical use. Fut Med Chem. 2009;1:1643–1670. PubMed PMC

Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc Res. 2000;47:529–536. PubMed

Hruskova K, Kovarikova P, Bendova P, Haskova P, Mackova E, Stariat J, Vavrova A, Vavrova K, Simunek T. Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis. Chem Res Toxicol. 2011;24:290–302. PubMed

Charkoudian LK, Pham DM, Franz KJ. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J Am Chem Soc. 2006;128:12424–12425. PubMed

Jansova H, Bures J, Machacek M, Haskova P, Jirkovska A, Roh J, Wang Q, Franz KJ, Kovarikova P, Simunek T. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology. 2016;350-352:15–24. PubMed PMC

Jansová H, Macháček M, Wang Q, Hašková P, Jirkovská A, Potůčková E, Kielar F, Franz KJ, Simůnek T. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radic Biol Med. 2014;74:210–221. PubMed PMC

Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57:547–583. PubMed

Kielar F, Helsel ME, Wang Q, Franz KJ. Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics. 2012;4:899–909. PubMed PMC

Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res. 1976;98:367–381. PubMed

Kovaríková P, Klimes J, Stĕrba M, Popelová O, Mokrý M, Gersl V, Ponka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci. 2005;28:1300–1306. PubMed

Kovaríková P, Mrkvicková Z, Klimes J. Investigation of the stability of aromatic hydrazones in plasma and related biological material. J Pharm Biomed Anal. 2008;47:360–370. PubMed

Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail. 2010;3:451–458. PubMed

Kruszewski M. The role of labile iron pool in cardiovascular diseases. Act Biochem Pol. 2004;51:471–480. PubMed

Liaudet L, Calderari B, Pacher P. Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. Heart Fail Rev. 2014;19:815–824. PubMed

Lieu PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Mol Aspects Med. 2001;22:1–87. PubMed

Mann DL, Kent RL, Parsons B, Cooper G.t. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804. PubMed

Mladenka P, Simunek T, Hubl M, Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic Res. 2006;40:263–272. PubMed

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761. PubMed

Rathore N, John S, Kale M, Bhatnagar D. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res. 1998;38:297–303. PubMed

Reif DW. Ferritin as a source of iron for oxidative damage. Free Radic Biol Med. 1992;12:417–427. PubMed

Remiao F, Carmo H, Carvalho F, Bastos ML. Copper enhances isoproterenol toxicity in isolated rat cardiomyocytes: effects on oxidative stress. Cardiovasc Toxicol. 2001;1:195–204. PubMed

Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc. 2008;3:1125–1131. PubMed

Rona G, Chappel CI, Balazs T, Gaudry R. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch Pathol. 1959;67:443–455. PubMed

Seo YJ, Lee JW, Lee EH, Lee HK, Kim HW, Kim YH. Role of glutathione in the adaptive tolerance to H2O2. Free Radic Biol Med. 2004;37:1272–1281. PubMed

Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol. 2005;39:345–354. PubMed

Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, Hroch M, Haskova P, Ponka P, Gersl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br J Pharmacol. 2008;155:138–148. PubMed PMC

Sterba M, Popelová O, Simůnek T, Mazurová Y, Potácová A, Adamcová M, Guncová I, Kaiserová H, Palicka V, Ponka P, Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology. 2007;235:150–166. PubMed

Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502–522. PubMed

Voogd A, Sluiter W, van Eijk HG, Koster JF. Low molecular weight iron and the oxygen paradox in isolated rat hearts. J Clin Invest. 1992;90:2050–2055. PubMed PMC

Wood JC. Cardiac complications in thalassemia major. Hemoglobin. 2009;33(Suppl 1):S81–86. PubMed PMC